The  Pompe disease market  is experiencing steady growth driven primarily by advancements in enzyme replacement therapies (ERT) and increasing awareness about this rare genetic disorder. Newer second-generation ERTs, such as cipaglucosidase alfa, have shown improved efficacy and patient outcomes, expanding treatment options beyond the traditional therapies. Additionally, government...